[1
]
From the Departments of Public Health and Primary Care (D.F.E., P.D.P.P., A.C.A.),
Oncology (D.F.E., P.D.P.P.), and Medical Genetics (M.T.), University of Cambridge,
Cambridge, the Centre for Genomic Medicine, Institute of Human Development, Manchester
Academic Health Science Centre, University of Manchester and St. Mary's Hospital,
Manchester (D.G.R.E.), and the Division of Genetics and Epidemiology, Institute of
Cancer Research, London (N.R.) - all in the United Kingdom; the Departments of Oncological
Sciences (S.V.T.) and Dermatology (D.E.G.), Huntsman Cancer Institute, University
of Utah School of Medicine, Salt Lake City; the Basser Research Center for BRCA and
Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania,
Philadelphia (K.L.N., S.M.D.); the Department of Human Genetics and Department of
Pathology, Leiden University Medical Center, Leiden, the Netherlands (P.D.); the Department
of Obstetrics and Gynecology, Division of Tumor Genetics, Klinikum rechts der Isar,
Technische Universität München, Munich, Germany (A.M.); the Department of Laboratory
Medicine and Pathology, Mayo Clinic, Rochester, MN (F.J.C.); the Department of Pathology,
School of Biomedical Sciences, Faculty of Medicine, Dentistry, and Health Sciences
at the University of Melbourne, Parkville, VIC (M.S.), and the QIMR Berghofer Medical
Research Institute, Herston, QLD (G.C.-T.) - both in Australia; the Clinical Genetics
Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan
Kettering Cancer Center, New York (M.R.); and the Program in Cancer Genetics, Departments
of Human Genetics and Oncology, the Lady Davis Institute for Medical Research, and
the Research Institute of the McGill University Health Center, McGill University,
Montreal (W.D.F.).